Emphysema,
a lung disease is characterized by the shortness of breath, thereby, damaging
the air sacs in the lungs. The disease leads to rupture and weakening of inner
walls of the air sacs over the period. The disease involves the reduction in
the surface area of the lungs which in turn reduces the amount of oxygen
reaching the bloodstream. Hence, during exhalation, the alveoli do not function
properly leaving the air trapped in the lungs, leaving no space for oxygen-rich
air to enter the lungs. Emphysema and chronic bronchitis are together known as
the Chronic Obstructive Pulmonary Disease (COPD). The patients suffering from
emphysema also have chronic bronchitis. The major causes of emphysema are
exposure to air pollutants, chemical fumes, and dust and smoking. The condition
can be diagnosed through various tests such as imaging tests that include chest
X-ray and CT scan and the lung function test.
The global emphysema
market is mainly driven by the high prevalence of respiratory diseases
such as chronic bronchitis, emphysema, and others and a huge demand for
treatment including smoking cessation drugs and antibiotics. Additionally, the
rising availability of diagnostic services for respiratory illness also fuels
the growth of the market.
According to the World Health Organization, COPD affects
nearly 210 million people which is attributed to the increasing population in
urban areas across the globe and growing number of tobacco smokers.
The global emphysema market is expected to grow at a CAGR
of 6.1% during the forecast period.
Segments
The global emphysema market is segmented
on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is
segmented into centrilobular and panlobular emphysema.
On the basis of diagnosis, the market is
segmented into imaging test, lung function test, and others. The imaging test
is further segmented into chest X-ray and CT scan.
On the basis of treatment, the market is
segmented into medications, therapy, and surgery. Medications are further
segmented into smoking cessation drugs, bronchodilators, inhaled steroids,
antibiotics, and leukotriene modifiers. Therapy is further segmented into
pulmonary rehabilitation, nutrition therapy, gene therapy, and supplemental
oxygen. Surgery is further segmented into lung volume reduction surgery, lung
transplant, and bullectomy.
On the basis of end-user, the market is
segmented into hospitals and clinics, surgical centers, and others.
Regional Analysis of the Global
Emphysema
Market
The American emphysema market is
segmented into two regions, namely, North America and South America. North
America, being the largest market, is mainly driven by the increasing use of
imaging test and lung function test for the diagnosis of the disease and huge
population base diagnosed with COPD. Furthermore, the U.S. is the largest
market in North America owing to the presence of large number of market players
manufacturing medications for emphysema and increasing awareness about risk
factors and cases of the disease. The American Lung Association stated that in
the U.S., COPD is the fourth leading cause of deaths. Canada is expected to be
the fastest growing market which is driven by the overall increasing demand for
diagnostic medical devices with progress in the medical device sector. South
America is expected to be the fastest growing market due to technologically
advanced devices for diagnosis and the increasing demand for treatment options
of respiratory diseases
The European emphysema market exhibits
a positive growth with an increasing emphasis on the diagnosis of chronic
respiratory conditions such as the COPD and asthma and increasing focus on
research and development activities for the treatment of respiratory diseases.
Germany and the U.K. are the major contributors to the growth of the market.
Additionally, increasing expenditure in healthcare by major countries in Europe
also accelerates the growth of the market.
Asia Pacific is expected to be
the fastest growing market whose growth is attributed to a huge demand for lung
function test and other diagnostic tests and the increasing focus on early
diagnosis and treatment of lung diseases. Furthermore, other factors
contributing to the growth of the market are lifestyle changes, the influence of
western culture among the adults, and addiction to smoking. Additionally,
rising environmental pollution and exposure to harmful chemicals also attribute
to the growth of the market.
The Middle Eastern and African
market for emphysema exhibits a steady rise with an increase in the number of
healthcare facilities providing treatment for the chronic condition and the
flourishing growth of medical device sector especially the diagnostic devices
such as MRI and CT. In the African region, the awareness about COPD is
increasing and is fueling the growth of the market.
Key Players in the Global
Emphysema Market
Some of the key players in this
market are Intrexon Corporation, Pulmonx Inc., Halozyme Therapeutics, Inc.,
Mariposa Health Limited, PneumRx, Uptake Medical Corporation, Icure
Pharmaceuticals, Inc., Pfizer, Inc., BTG International’s, Olympus Corporation,
Kamada Limited, Emphasys Medical, Inc. and others.
Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report
